Compare Citius Pharmaceuticals Inc (CTXR) vs Google Inc (GOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Google Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Google Inc trades at $355.02 (market cap $4.37T). The key difference: Google Inc is far larger — about 298497.3× Citius Pharmaceuticals Inc's market cap, and Google Inc pays a 0.25% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | GOOG | |
|---|---|---|
Market Cap | $14.64M | $4.37T |
Sector | Health | Technology |
52-Week High | $1.82 | $399.06 |
52-Week Low | $0.53 | $183.10 |
Enterprise Value | $10.86M | $4.34T |
Volume | — | 1,511,127 |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Alphabet (GOOG) trades at $350.67, down 1.23% amid bearish technical signals, though fundamentals remain robust with strong earnings beats and 32.8% net margin. Revenue grew to $402.84B in 2025, while analyst consensus is overwhelmingly bullish with an 86.84% buy rating and $457.50 price target. Recent news highlights AI advancements and regulatory scrutiny.
Outlook is positive given earnings momentum and AI leadership, but risks include regulatory probes and high valuation multiples. The stock offers growth potential with disciplined risk management advised amid technical weakness and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →
